Delamanid is a new medication that is presently classified as a D2 drug., and its use is recommended in adults for a maximum of six months. It can be added to an OBR (optimized background regimen) at the recommended doses, under adequate clinical monitoring that includes the measurement of QT intervals in ECG. The WHO has recently approved the use of this drug or children above six years of age, given that PK (pharmacokinetic) data having become successfully available.
This also helps to increase sputum smear and culture conversions to have success rates at the end of treatment, in adults, though much still needs more data to be gathered, especially with regards to drug-to-drug interactions and potential cardiotoxicity. Together with bedaquiline, as well as other core second-line drugs such as fluoroquinolones and clofazimine, it may increase the QT interval in ECG tracings.
Delamanid is used in the following conditions:
- Pulmonary multidrug-resistant tuberculosis